Sermorelin and Cardiovascular Research: GH Axis, IGF-1 and Cardiac Biology UK 2026

This article is for Research Use Only. Sermorelin is a research peptide not approved for human therapeutic use in the UK. All information is provided for scientific and educational purposes only.

Introduction: The GH Axis and Cardiovascular Biology

The somatotropic axis — encompassing growth hormone (GH), growth hormone-releasing hormone (GHRH), and insulin-like growth factor-1 (IGF-1) — exerts profound influence on cardiovascular physiology. Adult GH deficiency, characterised by the progressive decline of GH secretion known as somatopause, is associated with a constellation of cardiovascular risk factors including increased visceral adiposity, dyslipidaemia, endothelial dysfunction, and altered cardiac morphology. Research into GHRH analogues such as sermorelin has therefore expanded beyond growth biology to encompass their potential role in cardiovascular research models.

Sermorelin (GHRH 1-29 NH₂) is the bioactive N-terminal fragment of endogenous GHRH, capable of binding and activating the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs to stimulate pulsatile GH secretion. In cardiovascular research contexts, the compound is studied for its downstream effects on IGF-1 signalling in cardiomyocytes, vascular endothelium, and smooth muscle, as well as for direct extra-pituitary actions on cardiac tissue.

Direct Cardiac Effects of GH and IGF-1

Cardiomyocytes express both GH receptors (GHR) and IGF-1 receptors (IGF-1R), making the heart a direct target of somatotropic axis signalling. GH exerts anabolic effects on the myocardium, promoting cardiomyocyte hypertrophy, contractile protein synthesis, and calcium handling efficiency. Pathologically, excess GH (as in acromegaly) produces concentric hypertrophy and eventual cardiomyopathy. However, at physiological levels, GH-driven cardiac effects appear adaptive rather than maladaptive.

IGF-1, the primary peripheral mediator of GH action, binds IGF-1R on cardiomyocytes to activate the PI3K–Akt pathway. This signalling cascade promotes physiological cardiac hypertrophy, enhanced contractility, and cardiomyocyte survival. Research in GH-deficient animal models demonstrates reduced stroke volume, impaired systolic and diastolic function, and increased apoptotic susceptibility in cardiomyocytes — deficits that are partially reversible by GH or IGF-1 restoration. Sermorelin, by stimulating endogenous GH secretion and consequently IGF-1 production, represents an upstream approach to restoring this signalling milieu in research models.

Somatopause and Cardiovascular Risk: The Research Case for GH Restoration

Somatopause — the age-related decline in GH pulse amplitude and IGF-1 levels beginning in the third to fourth decade — is increasingly recognised as a contributor to age-related cardiovascular risk. Epidemiological research suggests that low IGF-1 levels are associated with increased risk of ischaemic heart disease, heart failure, and cardiovascular mortality in population studies, though causality and confounding remain areas of active investigation.

Mechanistic research in aged rodent models demonstrates that the somatopause phenotype is accompanied by:

• Increased visceral adiposity — a recognised driver of insulin resistance, dyslipidaemia, and systemic inflammation
• Endothelial dysfunction — reduced nitric oxide bioavailability and impaired vasodilation, partly attributable to reduced IGF-1 stimulation of endothelial nitric oxide synthase (eNOS)
• Altered lipoprotein profiles — elevated LDL-C, reduced HDL-C, and increased triglycerides in GH-deficient models
• Reduced left ventricular mass and ejection fraction — consistent with the direct anabolic deficit in the GH-deficient heart

Sermorelin, by augmenting endogenous GH pulsatility through pituitary GHRH-R stimulation, represents a physiologically grounded approach to studying whether somatopause-associated cardiovascular phenotypes are reversible through axis restoration.

Sermorelin in Preclinical Cardiovascular Models

Preclinical research has begun to characterise direct and indirect cardiovascular effects of GHRH/sermorelin administration. Studies in GH-deficient (dwarf) rats demonstrate that GHRH analogue treatment restores cardiac output, myocardial contractility indices, and IGF-1 levels toward age-matched eugonadal controls. Importantly, these effects appear mediated both through pituitary GH release and through direct GHRH-R signalling in cardiac tissue itself — an extra-pituitary pathway of growing interest.

Research by Schally and colleagues established that GHRH receptors are expressed in myocardial tissue, including cardiomyocytes and cardiac fibroblasts. Local GHRH-R activation in cardiac tissue may mediate cardioprotective effects independent of pituitary GH release, including anti-apoptotic signalling, reduced oxidative stress, and modulation of inflammatory cytokine expression (including TNF-α and IL-6 reduction). This dual mechanism — pituitary and cardiac — distinguishes GHRH analogues from direct GH or IGF-1 administration in research design.

Endothelial Biology and Nitric Oxide Pathway Research

Endothelial function is a sentinel metric of cardiovascular health, and the GH/IGF-1 axis is an established regulator of vascular tone. IGF-1 stimulates eNOS through PI3K–Akt-dependent phosphorylation, increasing nitric oxide production and promoting vasodilation. In GH-deficient states, reduced eNOS activation contributes to endothelial dysfunction and increased arterial stiffness — measurable by flow-mediated dilation (FMD) and pulse wave velocity (PWV) in human studies.

Research in aged animal models demonstrates that GHRH analogue treatment can partially restore FMD responses, suggesting that endothelial IGF-1 signalling is restored downstream of the pituitary effect. Additionally, reduced endothelial expression of adhesion molecules (ICAM-1, VCAM-1) has been observed following GH axis restoration, suggesting a reduction in pro-atherogenic vascular inflammation — a finding of mechanistic interest in age-related atherosclerosis research.

Cardiac Fibrosis and Remodelling Research

Pathological cardiac remodelling — characterised by cardiomyocyte hypertrophy, apoptosis, and interstitial fibrosis — represents the final common pathway of diverse cardiac diseases including pressure overload, ischaemia-reperfusion (I/R) injury, and dilated cardiomyopathy. The GH axis modulates multiple steps in this remodelling cascade, and GHRH analogues have been investigated in relevant preclinical models.

In I/R injury models, administration of GHRH analogues prior to reperfusion reduces infarct size, attenuates cardiomyocyte apoptosis (reduced cleaved caspase-3, Bax/Bcl-2 ratio), and preserves ejection fraction compared to vehicle-treated controls. These effects appear mediated partly by PI3K–Akt survival signalling downstream of IGF-1R activation, and partly by direct GHRH-R signalling suppressing inflammatory kinase cascades (JNK, p38 MAPK) in cardiomyocytes.

Cardiac fibrosis — driven by TGF-β1-mediated myofibroblast activation — is also modulated by IGF-1 signalling. Research suggests that IGF-1 can both suppress TGF-β1 canonical (Smad) signalling and promote matrix metalloproteinase (MMP) activity to remodel established fibrotic matrix, though the net effect is context-dependent (fibrotic vs. anti-fibrotic) depending on model and timing. This complexity makes GHRH/sermorelin an interesting tool for dissecting GH axis contributions to cardiac fibrosis biology.

Lipid Metabolism and Atherosclerosis Research

GH deficiency in both humans and animal models produces an atherogenic lipid profile: elevated total and LDL cholesterol, reduced HDL cholesterol, increased triglycerides, and elevated Lp(a). GH exerts direct effects on hepatic lipoprotein metabolism, including upregulation of LDL receptor expression (increasing LDL clearance) and promotion of HDL-C production. By restoring GH pulsatility, sermorelin offers a research model for studying how normalisation of the GH axis alters hepatic lipid processing and downstream atherogenic risk.

In ApoE knockout mouse models of atherosclerosis — a standard tool in cardiovascular research — GH deficiency accelerates plaque formation, while GH restoration reduces plaque burden and improves plaque stability characteristics (reduced macrophage infiltration, increased smooth muscle and collagen content). Whether GHRH analogues replicate these plaque-stabilising effects through physiological GH restoration is an open research question of mechanistic interest.

Heart Failure Biology and GH Axis Research

Heart failure — characterised by reduced cardiac output, neurohormonal activation, and progressive ventricular remodelling — is associated with low circulating IGF-1 levels in epidemiological studies. The mechanism may involve downregulation of IGF-1R signalling in the failing heart, GH resistance (as occurs in critical illness and catabolic states), and reduced hepatic IGF-1 production. Conversely, IGF-1 supplementation in preclinical heart failure models improves cardiac function, reduces apoptosis, and attenuates maladaptive hypertrophy.

Sermorelin, as a physiological GHRH analogue that stimulates pulsatile rather than supraphysiological GH release, offers a research approach to studying whether axis normalisation (rather than pharmacological IGF-1 supplementation) can modulate heart failure phenotypes. Studies in cardiac-specific IGF-1R knockout mice — which develop accelerated cardiac ageing and contractile dysfunction — have established the fundamental importance of cardiomyocyte IGF-1 signalling, providing a rationale for upstream GHRH axis manipulation as a research strategy.

Metabolic Syndrome and Insulin Sensitisation

Metabolic syndrome — the clustering of central obesity, insulin resistance, dyslipidaemia, and hypertension — substantially elevates cardiovascular risk and shares significant mechanistic overlap with the GH-deficient phenotype. GH exerts complex, context-dependent effects on insulin sensitivity: acutely, GH promotes insulin resistance (counter-regulatory lipolysis), but in GH-deficient states, the dominant phenotype is adiposity-driven insulin resistance rather than direct GH-mediated antagonism.

Research demonstrates that restoration of GH pulsatility through GHRH analogues — by reducing visceral fat mass, improving lean body composition, and normalising adipokine profiles — can improve whole-body insulin sensitivity indirectly. This is distinct from the acute insulin-antagonising effects of high-dose exogenous GH and represents a key mechanistic rationale for studying endogenous GH axis restoration rather than pharmacological GH replacement in metabolic cardiovascular research models.

Comparative Research Design: Sermorelin vs Direct GH or IGF-1 Administration

A key consideration in cardiovascular research design is the mechanistic distinction between GHRH analogues (such as sermorelin) and direct GH or IGF-1 administration:

• Physiological pulsatility: Sermorelin preserves pulsatile GH secretion through natural somatostatin feedback regulation, avoiding the continuous, supraphysiological GH exposure that produces adverse cardiac effects (eccentric hypertrophy) in acromegaly. This is mechanistically superior for studying physiological GH axis effects on the cardiovascular system.
• Dual cardiac mechanism: GHRH-R expression in cardiac tissue means sermorelin may exert direct, pituitary-independent effects on cardiomyocytes and vascular cells — effects that direct IGF-1 administration would not replicate.
• Hepatic vs systemic IGF-1: Direct GH administration drives predominantly hepatic IGF-1 production (endocrine IGF-1), whereas GHRH-stimulated pulsatile GH may produce a different ratio of autocrine/paracrine vs circulating IGF-1, with potentially distinct cardiovascular tissue profiles.

Research Methodology Notes

In cardiovascular research utilising sermorelin, key methodological considerations include administration route (subcutaneous injection being standard in rodent models), dosing frequency (to replicate pulsatile rather than tonic GH stimulation), and cardiovascular endpoint selection. Standard preclinical endpoints include echocardiographic assessment of ejection fraction, fractional shortening, left ventricular mass, and diastolic function (E/A ratio, E/e’); pressure-volume loop analysis (for contractility indices); vascular FMD and PWV measurements; and histological assessment of myocardial fibrosis (Masson’s trichrome, picrosirius red), apoptosis (TUNEL), and cardiomyocyte cross-sectional area.

Biomarker profiling — including circulating GH peak amplitude, IGF-1, IGFBP-3, cardiac troponins, BNP/NT-proBNP, and inflammatory markers — provides mechanistic context for functional cardiovascular endpoints. In aged-animal cardiovascular models, baseline characterisation of somatotropic axis function (IGF-1 levels, GH pulse amplitude under stimulation testing) is essential to interpret sermorelin’s effects relative to the degree of somatopause present.

Regulatory and Safety Framing for Research

All research utilising sermorelin is conducted under institutional research governance frameworks. In the UK, research peptide supply operates under MHRA statutory exemptions for non-clinical research purposes. Sermorelin is not licensed for therapeutic use in the UK and is not approved for human clinical use outside designated investigational new drug (IND) or clinical trial frameworks. All animal research must comply with the Animals (Scientific Procedures) Act 1986 and obtain appropriate Home Office project licences. No human cardiovascular dosing protocols or clinical recommendations are extrapolated from this research overview.